HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallacher, S. J Articles by Boyle, I. T Search for Related Content PubMed Articles by Gallacher, S. J Articles by Boyle, I. T

Acute effects of intravenous 1-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man

Gallacher SJ, Cowan RA, Fraser WD, Logue FC, Jenkins A. Boyle IT. Acute effects of intravenous 1-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man. Eur J Endocrinol 1994;130:141–5. ISSN 0804–4643

The acute effects of a single intravenous injection of 2 µg of 1-hydroxycholecalciferol (alfacalcidol) were studied for a 24-h period in six normal males (mean age 33 years), six women with primary hyperparathyroidism (mean age 72 years) and six women with established osteoporosis (mean age 63 years). In all three groups, serum calcitriol levels rose to a peak 2–3 h after administration of alfacalcidol. Basal levels were highest in the primary hyperparathyroidism group at (mean ±SEM) 81±2 vs 62±12 (normal males) (p<0.05) and 56±5 pmol/l (osteoporosis) (p<0.01). Highest peak levels were found also in the primary hyperparathyroidism group at 150±15 vs 114±15 (normal males) (p<0.05) and 127 ± 1 5 pmol/l (osteoporosis) (p<0.01). The rise in calcitriol was higher in the primary hyperparathyroidism group than either the normal males or osteoporotic patients (p<0.05). No significant differences were evident in basal serum calcidiol concentrations among the three treatment groups. As might be expected, highest basal concentrations of parathyroid hormone (PTH). serum calcium and serum osteocalcin were noted in the primary hyperparathyroid group (PTH: 17.1±7.7 vs 1.9±0.5 (normal males) (p<0.01) and 2.1±0.3 pmol/l (osteoporosis) (p<0.01): calcium: 3.06±0.08 vs 2.50±0.02 (normal males) (p<0.01) and 2.43±0.02 mmol/l (osteoporosis) (p<0.01): osteocalcin: 1.10±0.08 vs 0.56±0.16 (normal males) (p<0.05) and 0.53±0.21 nmol/l (osteoporosis) (p<0.05). Following treatment with alfacalcidol, no significant change was observed in PTH, calcium or osteocalcin serum concentrations in any group. These results show that maximal conversion of alfacalcidol to calcitriol occurs within a few hours of administration of alfacalcidol in normal males and patients with primary hyperparathyroidism and osteoporosis. Whilst this may reflect differences in activity of the enzyme 2 5-hydroxylase among these groups, other explanations, such as differences in calcitriol clearance, cannot be excluded.

SJ Gallacher, University Department of Medicine, Queen Elizabeth Building, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK

This article has been cited by other articles:

				L. Brandi, M. Egfjord, and K. Olgaard Pharmacokinetics of 1,25(OH)2D3 and 1{alpha}(OH)D3 in normal and uraemic men Nephrol. Dial. Transplant., May 1, 2002; 17(5): 829 - 842. [Abstract] [Full Text] [PDF]